TR201009396A2 - Desloratadine granules - Google Patents

Desloratadine granules

Info

Publication number
TR201009396A2
TR201009396A2 TR2010/09396A TR201009396A TR201009396A2 TR 201009396 A2 TR201009396 A2 TR 201009396A2 TR 2010/09396 A TR2010/09396 A TR 2010/09396A TR 201009396 A TR201009396 A TR 201009396A TR 201009396 A2 TR201009396 A2 TR 201009396A2
Authority
TR
Turkey
Prior art keywords
desloratadine
granules
polymorph
enantiomer
solvate
Prior art date
Application number
TR2010/09396A
Other languages
Turkish (tr)
Inventor
Bi̇lgi̇ç Mahmut
Original Assignee
Bi̇lgi̇ç Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bi̇lgi̇ç Mahmut filed Critical Bi̇lgi̇ç Mahmut
Priority to TR2010/09396A priority Critical patent/TR201009396A2/en
Priority to PCT/TR2011/000242 priority patent/WO2012064300A2/en
Publication of TR201009396A2 publication Critical patent/TR201009396A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Mevcut buluş, desloratadin veya farmasötik olarak kabul edilebilir bir tuzu, solvatı, türevi, polimorfu, hidratı veya enantiyomerinin terapötik olarak etkili bir miktarını içeren granüller ve bunların üretim yöntemi ile ilgilidir.The present invention relates to granules containing a therapeutically effective amount of desloratadine or a pharmaceutically acceptable salt, solvate, derivative, polymorph, hydrate or enantiomer and their method of manufacture.

TR2010/09396A 2010-11-11 2010-11-11 Desloratadine granules TR201009396A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
TR2010/09396A TR201009396A2 (en) 2010-11-11 2010-11-11 Desloratadine granules
PCT/TR2011/000242 WO2012064300A2 (en) 2010-11-11 2011-11-03 Desloratadine granules

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2010/09396A TR201009396A2 (en) 2010-11-11 2010-11-11 Desloratadine granules

Publications (1)

Publication Number Publication Date
TR201009396A2 true TR201009396A2 (en) 2012-05-21

Family

ID=45491748

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2010/09396A TR201009396A2 (en) 2010-11-11 2010-11-11 Desloratadine granules

Country Status (2)

Country Link
TR (1) TR201009396A2 (en)
WO (1) WO2012064300A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016140630A1 (en) * 2015-03-05 2016-09-09 PHARMACTIVE ILAÇ SANAYI VE TlCARET A. Ş. An effervescent composition comprising levocetirizine and pseudoephedrine
CN111398505B (en) * 2020-04-28 2022-04-08 健民药业集团股份有限公司 Method for simultaneously detecting contents of five components of traditional Chinese medicine for treating infantile enuresis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985003707A1 (en) 1984-02-15 1985-08-29 Schering Corporation 8-CHLORO-6,11-DIHYDRO-11-(4-PIPERIDYLIDENE)-5H-BENZO AD5,6 BDCYCLOHEPTA AD1,2-b BDPYRIDINE AND ITS SALTS, PROCESSES FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS
TW522014B (en) 1997-02-07 2003-03-01 Sepracor Inc Lactose-free, non-hygroscopic and anhydrous pharmaceutical unit dosage form containing descarboethoxyloratadine
US6100274A (en) * 1999-07-07 2000-08-08 Schering Corporation 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
WO2001045668A2 (en) 1999-12-20 2001-06-28 Schering Corporation Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
US20070014855A1 (en) 2005-07-12 2007-01-18 Rahul Gawande S Stable desloratadine compositions
US20070048373A1 (en) * 2005-08-30 2007-03-01 Cima Labs Inc. Dried milled granulate and methods
CA2541045A1 (en) * 2006-03-24 2007-09-24 Pharmascience Inc. A descarbonylethoxyloratadine containing pharmaceutical composition
WO2010060635A2 (en) * 2008-11-28 2010-06-03 Krka, D.D., Novo Mesto Solid pharmaceutical composition comprising at least one stabilizing agent

Also Published As

Publication number Publication date
WO2012064300A2 (en) 2012-05-18
WO2012064300A3 (en) 2012-08-02

Similar Documents

Publication Publication Date Title
NL301201I2 (en) Asciminib or a pharmaceutically acceptable salt thereof, such as asciminib hydrochloride
NL301191I2 (en) voxelotor or a tautomer or pharmaceutically acceptable salt thereof
NL301157I2 (en) odevixibat or a pharmaceutically acceptable salt thereof
NO2023040I1 (en) Atogepant or a pharmaceutically acceptable salt thereof
LTPA2017039I1 (en) Pyrolopyrimidine compounds as inhibitors of CDK
NL300901I2 (en) pibrentasvir or a pharmaceutically acceptable salt thereof
PH12014502733A1 (en) Neprilysin inhibitors
HK1192247A1 (en) Heterocyclic compounds as kinase inhibitors
HK1185879A1 (en) Pharmaceutically active compounds as axl inhibitors axl
BR302013000237S1 (en) "EARPHONE SETTING"
MX2020005498A (en) Cdk inhibitors.
PH12015500460A1 (en) Coated pharmaceutical composition containing regorafenib
EA201490161A1 (en) CONNECTIONS - SIGNAL INHIBITORS, MEDIED BY THE NOTCH RECEPTOR
EP2740478A4 (en) Sustained-release preparation of ivabradine or pharmaceutically acceptable salts thereof
EP2648519A4 (en) Novel polymorph of nilotinib hydrochloride
IT1402824B1 (en) PACK OF CIGARETTES.
IL223131A0 (en) Heterocyclic compounds as janus kinase inhibitors
EP2588106A4 (en) Sustained-release pharmaceutical composition containing pramipexole or pharmaceutically acceptable salt thereof with improved stability
EA201300034A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING IMATINIB OR ITS PHARMACEUTICALLY ACCEPTABLE SALT, AND WAYS TO OBTAIN THEM
IL250725A0 (en) Difluorolactam compounds for ep4-mediated osteo related diseases and conditions
UA113086C2 (en) PRAZOLE COMPOUNDS AS SGLT1 INHIBITORS
EP2611806A4 (en) Deuterium-enriched heterocyclic compounds as kinase inhibitors
IT1398244B1 (en) PACK OF CIGARETTES.
EP2611788A4 (en) Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use
MX359399B (en) 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS.